{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003087","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.308644+00:00","generated_at":"2026-05-21T23:50:03.589066+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"BeyondSpring Q1 net loss from continuing ops $2.6M; Plinabulin data show promise in PD-1 resistant cancers","bullets":["Net loss from continuing ops $2.6M, up 24% YoY; R&D expense $0.9M, G&A $1.7M.","Plinabulin combinations showed durable responses in metastatic NSCLC and Hodgkin lymphoma failing PD-1/L1 inhibitors.","SEED's RBM39 degrader achieved complete tumor regression in Ewing sarcoma models; IND filing on track for mid-2025.","SEED reported as discontinued ops after Jan 2025 sale of Series A-1 shares; BeyondSpring retains ~40% stake.","Phase 1 trial of Plinabulin + PD-1 inhibitor + radiation at MD Anderson showed >19-month duration in heavily pretreated Hodgkin lymphoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003087","json":"https://secwatch.observer/filing/0001171843-25-003087.json","markdown":"https://secwatch.observer/filing/0001171843-25-003087.md","text":"https://secwatch.observer/filing/0001171843-25-003087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/0001171843-25-003087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325003087/f8k_051225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:50:03.589066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}